

REMARKS

As amended, claims 1 and 2 are directed to a method of assigning a TNFRSF1A haplotype to an individual. Support for these amendments can be found in the specification as originally filed at p. 16, lines 11-16; p. 16, lines 22-23; and p. 16, lines 28-31.

As amended, claim 20 is directed to an isolated polynucleotide comprising a TNFRSF1A isogene encoding a TNFRSF1A polypeptide with a domain capable of binding TNF α , or its complement. Support for this amendment can be found in the specification as originally filed at p. 2, lines 42-34, the claim as originally found and pp 39-40. New claims 35-39, which depend from claim 20, are directed to subject matter found in the original specification in Table 3, p. 36 and Table 5, p. 39-40. It is respectfully submitted that the new claims do not introduce new matter and their entry is respectfully requested.


Claim 24, as amended, is directed to an isolated fragment of a TNFRSF1A isogene comprising at least 15 nucleotides. Support for this amendment is found in the claim as originally filed.

Amended claim 25 is directed to an isolated polynucleotide comprising a TNFRSF1A coding sequence. Support for this amendment is found in the claim as originally filed.

Should any questions arise, or if Applicants or Applicants' Attorney can facilitate examination of this Application, please contact the undersigned Attorney at the phone number below.

Reg. No. 47,934
Tel. No. 203-786-3421
s.shaner@genaissance.com

Respectfully Submitted,



Sandra L. Shaner
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511